Several recent policy proposals are placing new pressures on the 340B drug pricing program, a decades-old federal initiative many hospitals and health systems depend on to offset the costs of care for ...
The 340B program, enacted by Congress in 1992, requires pharmaceutical companies to sell medications to rural hospitals at ...
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s estimates, and HRSA should delay the program’s ...
AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.
Johnson & Johnson must scrap a pharmaceutical rebate initiative for hospitals participating in the 340B Drug Discount Program or risk federal sanctions, the Health Resources and Services ...
The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs. The program has proved a flash point between drugmakers and providers, as ...
An obscure, supposedly free federal program is blowing a hole in state budgets – by depriving state governments of billions in corporate tax revenue and inflating costs for their public employee ...
The American Hospital Association wants the Health Resources and Services Administration to levy monetary penalties against Johnson & Johnson if the drug company continues with its plan to give 340B ...
The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...
Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback